eyeforpharma is now Reuters Events - LEARN MORE
Rewarding The Best In Pharma
Fearless campaigners, patient-focused visionaries, innovative customer-focused projects; just a few of the pockets of excellence recognized by the eyeforpharma awards
Every innovation starts with an idea, often a very simple one. Nurtured by passion and creativity, nourished by the drive to always do things better, an idea can grow into a powerful force for good, for change, for a better life.
Each of the innovative programs recognized by this year’s eyeforpharma Awards was ignited by such a spark. Perhaps it was the desire to help patients overcome a barrier to better outcomes, or it was a need to support healthcare professionals to deliver better care, or even an exciting opportunity to partner in a unique way.
Judged by an expert panel of patients, customers and pharma executives, the eyeforpharma Awards seek to reward and recognize excellence and innovation – and above all, patient focus.
In the words of Christi Shaw, SVP and President, Lilly Bio-Medicines: “[They] recognize what really matters in the pharmaceutical industry: providing the maximum value to the greatest number of patients. This unique event galvanizes our industry, propelling it in the right direction. I encourage companies and leaders to support and enter – and, just as urgently, to applaud our colleagues who are shining a positive light on the industry as a result of the work they do.”
Read our articles on the 2018 European winners:
- Patient Advocate Award: Tireless Campaigner Wins Recognition
- Most Valuable Patient Initiative: Ipsen ‘Nets’ Patient-Focused Award
- Most Valuable HCP Initiative: Virtual Reality Gets Its Moment
- Most Valuable Collaboration: Life-Saving Vaccination Scheme Honored
- Lifetime Achievement Award: Visionary Leader Honored
North American Awards:
The winners of the North American Awards will be announced during eyeforpharma Philadelphia 2018 on 10-11 April 2018. To find out which entries were selected as finalists, visit the website.
Since you're here...
... and value our content, you should sign-up to our newsletter. Sign up here